METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Prostate cancer drug combo fails to show benefit in Late-Stage trial
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 participants in China. Unfortunate…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
Prostate cancer trial tests immune booster alongside standard hormone therapy
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) helps men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. Over 1,200 men participated. The study was stopped early, and …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 03:10 UTC
-
Chemo-Hormone combo boosts survival in advanced prostate cancer
Disease control CompletedThis study tested whether adding chemotherapy (docetaxel) to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men with cancer that had spread were randomly assigned to get hormone therapy alone or hormone therapy plus chemo. The main goal was to…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo extends life in advanced prostate cancer trial
Disease control CompletedThis study tested whether adding darolutamide to standard hormone therapy and chemotherapy helps men with metastatic prostate cancer that still responds to hormones. Over 1,300 men took part. The goal was to see if the combination improved overall survival. Results showed that da…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo slows advanced prostate cancer in major trial
Disease control CompletedThis study tested whether adding enzalutamide to standard hormone therapy (ADT) helps men with prostate cancer that has spread to other parts of the body. About 1,150 men took part. The goal was to see if the combination delayed cancer growth or death better than ADT alone. Resul…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New model uses PET scans to predict prostate cancer treatment success
Knowledge-focused CompletedThis study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:03 UTC